These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12867202)

  • 1. Gaps in the drug-free and methadone treatment program response to Hepatitis C.
    Strauss SM; Astone J; Vassilev ZP; Des Jarlais DC; Hagan H
    J Subst Abuse Treat; 2003 Jun; 24(4):291-7. PubMed ID: 12867202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The content and comprehensiveness of hepatitis C education in methadone maintenance and drug-free treatment units.
    Strauss SM; Astone JM; Hagan H; Des Jarlais DC
    J Urban Health; 2004 Mar; 81(1):38-47. PubMed ID: 15047782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nationwide survey of hepatitis C services provided by drug treatment programs.
    Strauss SM; Falkin GP; Vassilev Z; Des Jarlais DC; Astone J
    J Subst Abuse Treat; 2002 Mar; 22(2):55-62. PubMed ID: 11932130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outpatient drug treatment program directors' hepatitis C-related beliefs and their relationship to the provision of HCV services.
    Astone JM; Strauss SM; Hagan H; Des Jarlais DC
    Am J Drug Alcohol Abuse; 2004 Nov; 30(4):783-97. PubMed ID: 15624549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Provision of hepatitis C education in a nationwide sample of drug treatment programs.
    Astone J; Strauss SM; Vassilev ZP; Des Jarlais DC
    J Drug Educ; 2003; 33(1):107-17. PubMed ID: 12773028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injection drug users and the provision of hepatitis C-related services in a nationwide sample of drug treatment programs.
    Vassilev ZP; Strauss SM; Astone J; Des Jarlais DC
    J Behav Health Serv Res; 2004; 31(2):208-16. PubMed ID: 15255228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States.
    Strauss SM; Astone JM; Jarlais DD; Hagan H
    Drug Alcohol Depend; 2004 Mar; 73(3):227-36. PubMed ID: 15036545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating hepatitis C services into existing HIV services: the experiences of a sample of U.S. drug treatment units.
    Strauss SM; Astone JM; Des Jarlais DC; Hagan H
    AIDS Patient Care STDS; 2005 Feb; 19(2):78-88. PubMed ID: 15716639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study.
    Frimpong JA; D'Aunno T; Jiang L
    Am J Public Health; 2014 Jun; 104(6):e75-82. PubMed ID: 24825236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knowledge of and interest in hepatitis C treatment at a methadone clinic.
    Walley AY; White MC; Kushel MB; Song YS; Tulsky JP
    J Subst Abuse Treat; 2005 Mar; 28(2):181-7. PubMed ID: 15780548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using latent class analysis to identify patterns of hepatitis C service provision in drug-free treatment programs in the U.S.
    Strauss SM; Rindskopf DM; Astone-Twerell JM; Des Jarlais DC; Hagan H
    Drug Alcohol Depend; 2006 Jun; 83(1):15-24. PubMed ID: 16289523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States.
    Bini EJ; Kritz S; Brown LS; Robinson J; Calsyn D; Alderson D; Tracy K; McAuliffe P; Smith C; Rotrosen J
    J Subst Abuse Treat; 2012 Jun; 42(4):438-45. PubMed ID: 22035702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sociodemographic disparities in supplemental service utilization among male methadone patients.
    Wu E; El-Bassel N; Gilbert L; Piff J; Sanders G
    J Subst Abuse Treat; 2004 Apr; 26(3):197-202. PubMed ID: 15063913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Staff perspectives on facilitating the implementation of hepatitis C services at drug treatment programs.
    Munoz-Plaza CE; Strauss SM; Astone-Twerwll JM; Des Jarlais DC; Hagan H
    J Psychoactive Drugs; 2006 Sep; 38(3):233-41. PubMed ID: 17165366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services.
    Strauss SM; Astone-Twerell J; Munoz-Plaza CE; Des Jarlais DC; Gwadz M; Hagan H; Osborne A; Rosenblum A
    BMC Health Serv Res; 2007 Mar; 7():39. PubMed ID: 17346346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Access to treatment-related and support services in methadone treatment programs.
    Berkman ND; Wechsberg WM
    J Subst Abuse Treat; 2007 Jan; 32(1):97-104. PubMed ID: 17175403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C testing in substance use disorder treatment: the role of program managers in adoption of testing services.
    Frimpong JA; D'Aunno T
    Subst Abuse Treat Prev Policy; 2016 Apr; 11():13. PubMed ID: 27036115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment.
    Talal AH; Dimova RB; Seewald R; Peterson RH; Zeremski M; Perlman DC; Des Jarlais DC
    J Subst Abuse Treat; 2013 Jan; 44(1):115-9. PubMed ID: 22405884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities.
    Litwin AH; Soloway I; Gourevitch MN
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S339-45. PubMed ID: 15768345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Missed opportunities for hepatitis C testing in opioid treatment programs.
    Frimpong JA
    Am J Public Health; 2013 Jun; 103(6):1028-30. PubMed ID: 23597374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.